Can a new immunotherapy combo shrink Hard-to-Treat tumors?

NCT ID NCT04999761

Recruiting now Disease control Sponsor: Taiho Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are safe and tolerable, and to see if they can shrink tumors or slow their growth. The study includes multiple groups, each focusing on a specific cancer type or drug pairing, and will closely monitor side effects and treatment responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB122 (an experimental immunotherapy) alone or combined with other investigational drugs (TAS-116, TAS-120, TAS-115)
What this could lead to: If successful, this could help identify safer and more effective drug combinations for several hard-to-treat advanced cancers, potentially improving outcomes for many patients.
What could go wrong: This is an early-phase trial, so the treatments may not work as hoped or may cause unexpected side effects. Results from this small study will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma biliary tract cancer Biliary Tract Neoplasms colorectal adenocarcinoma colorectal cancer colorectal neoplasm esophageal cancer Esophageal Neoplasms gastric cancer gastric neoplasm head and neck cancer Head and Neck Neoplasms neoplasm Neoplasm Metastasis non-small cell lung carcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED OR METASTATIC SOLID TUMOR ALVEOLAR SOFT PART SARCOMA BILIARY TRACT CANCER COLORECTAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER HEAD AND NECK CANCER NON-SMALL CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Aichi, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Chiba, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Ehime, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Hokkaido, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Kanagawa, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Osaka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Shizuoka, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Tokyo, Japan
A site selected by Taiho Pharmaceutical Co., Ltd.
RECRUITING

Wakayama, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.